These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15449905)

  • 41. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.
    De Clercq E
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1800-22. PubMed ID: 15183346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Atazanavir: a review of its use in the management of HIV infection.
    Swainston Harrison T; Scott LJ
    Drugs; 2005; 65(16):2309-36. PubMed ID: 16266202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atazanavir: a novel HIV-1 protease inhibitor.
    Piliero PJ
    Expert Opin Investig Drugs; 2002 Sep; 11(9):1295-301. PubMed ID: 12225250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synthesis and anti-HIV activity of some [Nucleoside Reverse Transcriptase Inhibitor]-C5'-linker-[Integrase Inhibitor] heterodimers as inhibitors of HIV replication.
    Sugeac E; Fossey C; Ladurée D; Schmidt S; Laumond G; Aubertin AM
    J Enzyme Inhib Med Chem; 2004 Dec; 19(6):497-509. PubMed ID: 15662954
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emtricitabine: an antiretroviral agent for HIV infection.
    Bang LM; Scott LJ
    Drugs; 2003; 63(22):2413-24; discussion 2425-6. PubMed ID: 14609348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel inhibitors of HIV-1 integration.
    Witvrouw M; Van Maele B; Vercammen J; Hantson A; Engelborghs Y; De Clercq E; Pannecouque C; Debyser Z
    Curr Drug Metab; 2004 Aug; 5(4):291-304. PubMed ID: 15320701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigational antiretroviral drugs.
    Sen S; Mathur AG; Gupta RM; Kapila K; Chopra GS
    Recent Pat Antiinfect Drug Discov; 2008 Nov; 3(3):199-205. PubMed ID: 18991802
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Anti-HIV drugs].
    Koibuchi T
    Uirusu; 2013; 63(2):199-208. PubMed ID: 25366054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir.
    Minami R; Yamamoto M; Takahama S; Ando H; Miyamura T; Suematsu E
    J Infect Chemother; 2011 Apr; 17(2):183-8. PubMed ID: 20706762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New antiretroviral agents: looking beyond protease and reverse transcriptase.
    Miller MD; Hazuda DJ
    Curr Opin Microbiol; 2001 Oct; 4(5):535-9. PubMed ID: 11587929
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Small molecule inhibitor of HIV-1 nuclear import suppresses HIV-1 replication in human lymphoid tissue ex vivo: a potential addition to current anti-HIV drug repertoire.
    Glushakova S; Dubrovsky L; Grivel J; Haffar O; Bukrinsky M
    Antiviral Res; 2000 Aug; 47(2):89-95. PubMed ID: 10996396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
    Patel RV; Park SW
    Bioorg Med Chem; 2015 Sep; 23(17):5247-63. PubMed ID: 26116177
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
    Zheng PR; Xue H; Xiao ZY; Liu G
    Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.
    Sierra-Aragón S; Walter H
    Intervirology; 2012; 55(2):84-97. PubMed ID: 22286875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches.
    Tarrago-Litvak L; Andreola ML; Fournier M; Nevinsky GA; Parissi V; de Soultrait VR; Litvak S
    Curr Pharm Des; 2002; 8(8):595-614. PubMed ID: 11945161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIV-1 integration as a target for antiretroviral therapy: a review.
    Pluymers W; De Clercq E; Debyser Z
    Curr Drug Targets Infect Disord; 2001 Aug; 1(2):133-49. PubMed ID: 12455410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents.
    de Soultrait VR; Lozach PY; Altmeyer R; Tarrago-Litvak L; Litvak S; Andréola ML
    J Mol Biol; 2002 Nov; 324(2):195-203. PubMed ID: 12441099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic potential of peptide motifs against HIV-1 reverse transcriptase and integrase.
    Andréola ML
    Curr Pharm Des; 2009; 15(21):2508-19. PubMed ID: 19601847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.